ArticleCancer discovery2021
SWI/SNF Complex Mutations Promote Thyroid Tumor Progression and Insensitivity to Redifferentiation Therapies.
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 79 papers, 1 of them a synthesis that pooled it.
0numbers the graph read from it
0cells of the map it votes in
79citing papers in PubMed, 1 pooled it
5.1field-weighted citation impact, top 3% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
79 citing papers in PubMed, 1 synthesis or guideline pooled it, 107 citations in OpenAlex.
- The effect ofFrontiers in endocrinology · 2025Pooled it
- Selumetinib Plus Adjuvant Radioactive Iodine in Patients With High-Risk Differentiated Thyroid Cancer: A Phase III, Randomized, Placebo-Controlled Trial (ASTRA).Journal of clinical oncology : official journal of the American Society of Clinical Oncology · 2022Trial
- Enhancing Radioiodine Incorporation inThyroid : official journal of the American Thyroid Association · 2022Trial
- From bench to bedside: the evolving role of iodine in thyroid cancer management.Nature reviews. Endocrinology · 2026Review
- SMARCA4-deficient Anaplastic Thyroid Carcinoma: A Hitherto Unreported Case.Virchows Archiv : an international journal of pathology · 2026Article
- Genomics and Multi-Omics to Guide Clinical Management in Thyroid Cancer.International journal of molecular sciences · 2026Review
- Microenvironmental Control of Thyroid Cancer Plasticity and Radioiodine Resistance.International journal of molecular sciences · 2026Review
- Genomic alterations in pediatric tumors: clinical relevance and translational insights.Pediatric research · 2026Article
- The roles of chromatin remodeling and 3D genome organization in cancers: from mechanistic insights to emerging treatment options.Molecular cancer · 2026Review
- Activation of EZH2 Promoter Is Mediated by MAPK Signaling Regulated Transcription Factors in Anaplastic Thyroid Cancer.International journal of molecular sciences · 2026Article
- Understanding and overcoming innate and acquired MAPK inhibition resistance in anaplastic thyroid cancer.Cell reports. Medicine · 2026Article
- Cancer Stemness and Dedifferentiation in Anaplastic Thyroid Carcinoma: Insights into a Multigenic, Microenvironmental Network and the Role of CD44.Biomedicines · 2026Review
- Multidisciplinary team diagnosis and treatment of well-differentiated thyroid carcinoma: current landscape and future prospects.The oncologist · 2026Review
- Methyltransferase like 3 promotes thyroid folliculogenesisJournal of translational internal medicine · 2026Article
- Dedifferentiation and Redifferentiation of Follicular-Cell-Derived Thyroid Carcinoma: Mechanisms and Therapeutic Implications.Biomedicines · 2025Review
- BRAF V600E in thyroid cancer: navigating prognostic uncertainty and therapeutic opportunity.European thyroid journal · 2025Review
- Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.The Journal of clinical investigation · 2025Article
- Somatic genetic alterations in the development and progression in thyroid tumors of follicular cells.European thyroid journal · 2025Review
- Tissue-specific co-expression patterns of BAF complex genes across human endocrine and non-endocrine tissues.Endocrine connections · 2025Article
- Progression of Follicular Thyroid Carcinomas to Anaplastic Thyroid Carcinomas: Molecular and Clinicopathologic Characteristics with Comparison to Papillary Thyroid Carcinoma-Derived Anaplastic Thyroid Carcinomas.Endocrine pathology · 2025Article
19 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 2 institutions in 1 country.
Mahesh Saqcena *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Luis Javier Leandro-Garcia *Human Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Jesper L V MaagCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-2578-8872
Vatche TchekmedyianDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Gnana P KrishnamoorthyHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Prasanna P TamarapuHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Vera TiedjeHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Vincent ReuterCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0002-7967-976X
Jeffrey A KnaufHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4456-8792
Elisa de StanchinaAntitumor Assessment Core Facility, Memorial Sloan Kettering Cancer Center, New York, New York.
Bin XuDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.ORCID 0000-0003-4638-9835
Xiao-Hui LiaoDepartment of Medicine, The University of Chicago, Chicago, Illinois.
Samuel RefetoffDepartments of Medicine and Pediatrics and the Committee on Genetics, The University of Chicago, Chicago, Illinois.
Ronald GhosseinDepartment of Pathology, Memorial Sloan Kettering Cancer Center, New York, New York.
Ping ChiHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York.
Alan L HoDepartment of Medicine, Memorial Sloan Kettering Cancer Center, New York, New York.
Richard P KocheCenter for Epigenetics Research, Memorial Sloan Kettering Cancer Center, New York, New York.
James A FaginHuman Oncology and Pathogenesis Program, Memorial Sloan Kettering Cancer Center, New York, New York. faginj@mskcc.org.
Memorial Sloan Kettering Cancer Center · USUniversity of Chicago · US
Funding
X-RAY CRYSTALLOGRAPHYP30CA008748 · NCI · SLOAN-KETTERING INSTITUTE FOR CANCER RES · PI Hongbiao Carl Lekaye · 1985 to 2026
$347.4MSPORE in Thyroid CancerP50CA172012 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2014 to 2018
$10.3MTHYROID PHYSIOLOGY STUDIES OF INHERITED DISORDERSR01DK015070 · NIDDK · UNIVERSITY OF CHICAGO · PI ANTONIO C BIANCO, Alexandra Mihaela Dumitrescu · 1986 to 2026
$8.1MMOLECULAR PATHOPHYSIOLOGY OF THYROID CELL GROWTHR01CA050706 · NCI · UNIVERSITY OF CINCINNATI · PI FAGIN, JAMES A · 1995 to 2023
$7.5MTHYROID PHYSIOLOGY STUDIES OF INHERITED DISORDERSR37DK015070 · NIDDK · UNIVERSITY OF CHICAGO · PI REFETOFF, SAMUEL · 1989 to 2015
$5.6MEpigenetic mechanisms of transcriptional activation of a novel oncogenic ALK variant in cancerR01CA228216 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI CHI, PING · 2018 to 2022
$2.5MTranslational Research in Oncology Training ProgramT32CA160001 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI SAWYERS, CHARLES L. · 2011 to 2020
$2.0MTargeting MEK to Restore Radioiodine Efficacy for RAI-Refractory Thyroid CancerR01CA184724 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI HO, ALAN L. · 2015 to 2017
$1.7MMaximizing effectiveness of radioiodine therapy by inhibition of MAPK signalingR01CA173592 · NCI · SLOAN-KETTERING INST CAN RESEARCH · PI FAGIN, JAMES A · 2013 to 2014
$817kNCI NIH HHS P30 CA008748NCI NIH HHS P50 CA172012NCI NIH HHS R01 CA050706NCI NIH HHS R01 CA173592NCI NIH HHS R01 CA184724NCI NIH HHS R01 CA228216NCI NIH HHS T32 CA160001NIDDK NIH HHS R01 DK015070NIDDK NIH HHS R37 DK015070
Abstract
Mutations of subunits of the SWI/SNF chromatin remodeling complexes occur commonly in cancers of different lineages, including advanced thyroid cancers. Here we show that thyroid-specific loss of
Indexed as
AnimalsCell Line, TumorCellular Reprogramming TechniquesChromosomal Proteins, Non-HistoneDisease Models, AnimalMiceMice, Inbred StrainsMutationThyroid NeoplasmsTranscription FactorsChromosomal Proteins, Non-HistoneSWI-SNF-B chromatin-remodeling complexTranscription Factors
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.